Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK146D1 and AK112 in Advanced Breast Cancer
NCT07591090Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jul 2026
- Primary completion
- Sep 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of AK146D1 in breast cancer (2 arms), sponsored by Akeso, Inc. Primary endpoints: Dose Limiting Toxicities at 3 weeks, Adverse Events at 90 days and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
AK146D1
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07591090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07591090.